Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022

被引：0
|
作者：
Tibau, A. [1 ]
Hwang, T. J. [2 ]
Consolacion, M. [3 ]
Avorn, J. [4 ]
Kesselheim, A. [4 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Brigham & Womens Hosp, Div Urol Surg, Boston, TX USA
[3] Princess Margaret Canc Ctr, Med Oncol Dept, Toronto, ON, Canada
[4] Brigham & Womens Hosp, PORTAL Program Regulat Therapeut & Law, Pharmacoepidemiol & Pharmacoecomon Div, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1703P
引用
收藏
页码：S930 / S930
页数：1
相关论文
共 49 条
  • [1] Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies
    Tibau, Ariadna
    Hwang, Thomas J.
    Molto, Consolacion
    Avorn, Jerry
    Kesselheim, Aaron S.
    JAMA ONCOLOGY, 2024, 10 (05) : 634 - 641
  • [2] Value of Molecular Targets and Genome-Targeted Therapies FDA-Approved for Metastatic Breast Cancer, 2006-2023
    Tibau, Ariadna
    Hwang, Thomas J.
    Valiente, Consolacion Molto
    Avorn, Jerry
    Kesselheim, Aaron
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Clinical Value of Molecular Targets and Genome-Targeted Cancer Therapies Recommended by the National Comprehensive Cancer Network for Advanced Breast Cancer
    Tibau, Ariadna
    Hwang, Thomas J.
    Avorn, Jerry
    Kesselheim, Aaron
    CANCER RESEARCH, 2024, 84 (09)
  • [4] Trends in FDA-Approved Cancer Therapies
    Hilas, Olga
    US PHARMACIST, 2023, 48 (10) : 14 - 14
  • [5] Evaluation of Potential Therapeutic Targets with Experimental or FDA-approved Therapies in Thymic Tumor Microarrays
    Larijani, F. Ardeshir
    Hou, T.
    Maniar, R.
    Kuhar, M.
    Perna, F.
    Loehrer, P.
    Mesa, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S447 - S447
  • [6] OVERVIEW OF FDA-APPROVED ANTI CANCER DRUGS USED FOR TARGETED THERAPY
    Di Martino, S.
    Rainone, A.
    Troise, A.
    Di Paolo, M.
    Pugliese, S.
    Zappavigna, S.
    Grimaldi, A.
    Valente, D.
    WORLD CANCER RESEARCH JOURNAL, 2015, 2 (03)
  • [7] A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
    Sheikhi, Negar
    Bahraminejad, Maryam
    Saeedi, Mina
    Mirfazli, Seyedeh Sara
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 260
  • [8] Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
    Tibau, Ariadna
    Hwang, Thomas J.
    Avorn, Jerry
    Kesselheim, Aaron S.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 386
  • [9] Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
    Hou, Zhi-Jie
    Luo, Xi
    Zhang, Wei
    Peng, Fei
    Cui, Bai
    Wu, Si-Jin
    Zheng, Fei-Meng
    Xu, Jie
    Xu, Ling-Zhi
    Long, Zi-Jie
    Wang, Xue-Ting
    Li, Guo-Hui
    Wan, Xian-Yao
    Yang, Yong-Liang
    Liu, Quentin
    ONCOTARGET, 2015, 6 (08) : 6326 - 6340
  • [10] Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers
    Flores Monar, Gabriela Vanessa
    Reynolds, Thomas
    Gordon, Maxie
    Moon, David
    Moon, Chulso
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
12345